Melior Discovery publications
Christopher A. Lipinski
Science Direct, Elsevier, April 27, 2016
Lipinski CA, Litterman NK, Southan C, Williams AJ, Clark AM and Ekins S.
J. Med. Chem. 2014 Nov; Article ASAP.
Computational Prediction and Validation of an Expert's Evaluation of Chemical Probes Litterman NK, Lipinski CA, Bunin BA, Ekins S. J. Chem. Inf. Model., 2014 Sept; 54(10): 2996-3004.
The future of drug discovery: Two required supplements to current practices. Reaume AG, Lipinski CA. Pharma July 2013
MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo. Saporito MS, Ochman AR, Lipinski CA, Handler JA, Reaume AG. J Pharmacol Exp Ther. 2012 Jul;342(1):15-22.
The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes. Ochman AR, Lipinski CA, Handler JA, Reaume AG, Saporito MS. J Pharmacol Exp Ther. 2012 Jul;342(1):23-32.
Phenotypic in vivo screening to identify new unpredicted indication for existing drugs and drug candidates. Saporito MS, Lipinski CA, Reaume AG in Drug Repositioning: Bringing New Life to Shelved Assets. (John Wiley & Sons, Hoboken, NJ, USA) 2012. Barratt MD and Frail D (Eds).
Drug repurposing through nonhypothesis driven phenotypic screening. Reaume AG. Drug Disc. Today 2011 8(3-4):85-88.
theraTRACE®: A mechanism unbiased in vivo platform for phenotypic screening and frug repositioning. Saporito MS, Reaume AG. Drug Disc. Today 2011 8(3-4):89-95.
The anti-intellectual effects of intellectual property. Lipinski CA. Curr Opin Chem Biol. 2006 Aug;10(4):380-3.
If you are interested in learning more about Melior Publications, please contact firstname.lastname@example.org to start the conversation.